Jia, Jingquan
Howard, Lauren
Liu, Yingmiao
Starr, Mark D.
Brady, John C.
Niedzwiecki, Donna
Strickler, John H.
Nixon, Andrew B. http://orcid.org/0000-0003-3971-2964
Clinical trials referenced in this document:
Documents that mention this clinical trial
Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers
https://doi.org/10.1007/s00280-022-04404-8
Funding for this research was provided by:
Exelixis
Article History
Received: 22 September 2021
Accepted: 29 January 2022
First Online: 16 February 2022
Declarations
:
: John H. Strickler has received research funding from Abbvie, AstraZeneca, Bayer, Mereo BioPharma,Pfizer, Seattle Genetics (C/A), Bayer (H), Amgen, Seattle Genetics,Exelixis, AStar D3, Sanofi, Nektar, Abbvie, and Roche/Genentech,Daiichi-Sankyo (RF); Andrew B. Nixon has received research funding from Genentech, MedImmune/AstraZeneca, Medpacto, Seattle Genetics, HTG Molecular Diagnostics, and Promega Corporation and has received consultant/advisory compensation from Eli Lilly, GSK, Promega Corporation, Leap Therapeutics, and AdjuVolt Therapeutics. The other authors declare no potential conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in this study.